Skip to main content
ZJAMP Group Co., Ltd. logo

ZJAMP Group Co., Ltd. — Investor Relations & Filings

Ticker · 002758 ISIN · CNE100002029 LEI · 3003009OKT32LB5C0T64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,563 across all filing types
Latest filing 2019-04-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002758

About ZJAMP Group Co., Ltd.

https://www.znjtgf.com

ZJAMP Group Co., Ltd. specializes in the comprehensive distribution and supply chain management of agricultural production materials. The company’s core operations encompass the procurement, storage, and sale of essential inputs, including chemical fertilizers such as urea, potash, and compound fertilizers, as well as pesticides, seeds, and agricultural machinery. Beyond product distribution, the organization provides integrated technical services, modern logistics solutions, and agricultural consultancy to enhance crop yields and farming efficiency. By leveraging an extensive network of distribution centers and service stations, the group facilitates the stable supply of high-quality agricultural resources. Its business model focuses on bridging the gap between manufacturers and end-users through efficient resource allocation and value-added services.

Recent filings

Filing Released Lang Actions
关于2019年度对外借款及相关担保授权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhejiang Huatong Pharmaceutical Co., Ltd. regarding the authorization for external borrowings and related guarantees for the year 2019. It details the authorization limits for borrowings and guarantees, the approval process, and the board's opinion on these matters. There are no financial statements or comprehensive financial data presented, nor is this a report of financial results or a regulatory certification. The document is a formal announcement about financing authorizations and guarantees, which fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive details about financing authorizations rather than just announcing a report publication, so it is not an RPA. Therefore, the classification is CAP with high confidence.
2019-04-19 Chinese
独立董事提名人声明
Board/Management Information Classification · 95% confidence The document is a public statement from the board of Zhejiang Huatong Pharmaceutical Co., Ltd. nominating an independent director candidate. It contains detailed declarations about the nominee's qualifications and compliance with various regulatory requirements. There is no financial data, no report of financial performance, no voting results, no meeting materials, and no mention of a report being attached or published. The content is focused on board/management information, specifically about a nomination to the board. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is under 5,000 characters, but it is not an announcement of a report publication; it is a standalone statement about board nomination.
2019-04-19 Chinese
募集资金年度存放与使用情况鉴证报告（2018年度）
Regulatory Filings
2019-04-19 Chinese
专项审计说明（2018年度）
Regulatory Filings
2019-04-19 Chinese
发行股份购买资产暨关联交易预案
Capital/Financing Update Classification · 95% confidence The document is a detailed plan and proposal for a major asset purchase and related party transaction by Zhejiang Huatong Pharmaceutical Co., Ltd. It includes extensive information about the transaction parties, the background, the financial data of the target assets, the expected impact on the company, the payment method (issuance of shares), lock-up periods, and risk disclosures. The document repeatedly refers to this as a "重大资产重组预案" (major asset restructuring plan) and discusses the transaction as a significant asset acquisition and related party transaction, which is typical of a capital/financing update or restructuring announcement. It is not a full annual or interim report, nor an earnings release or audit report. It is a comprehensive transaction proposal document, not merely an announcement of a report. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length (15,000 characters) and content depth support this classification with high confidence.
2019-04-19 Chinese
关于本次交易前12个月内资产购买、出售情况的说明
Regulatory Filings Classification · 95% confidence The document is a formal statement from Zhejiang Huatong Pharmaceutical Co., Ltd. regarding asset purchase and sale activities within the past 12 months. It specifically clarifies that no major asset purchases or sales have occurred in that period. The content references regulatory rules about asset restructuring and cumulative calculations but does not present financial data, audit results, or detailed transaction data. It is an explanatory note related to a transaction but does not itself announce a merger or acquisition, nor does it provide financial statements or detailed management discussion. The document is short (746 characters) and serves as a regulatory compliance disclosure about asset transactions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-04-19 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.